Expand CLRB Menu
CLRB MENU

CLRB Latest Press Releases

-- March 27, 2024 --

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update Globe Newswire 6:40 AM

-- March 20, 2024 --

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 Globe Newswire 6:40 AM

-- March 14, 2024 --

Cellectar Biosciences to Present at the 36th Annual Roth Conference Globe Newswire 8:52 AM

-- March 4, 2024 --

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Globe Newswire 6:40 AM

-- February 7, 2024 --

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Globe Newswire 6:40 AM

-- January 30, 2024 --

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study Globe Newswire 6:40 AM

-- January 25, 2024 --

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million Globe Newswire 6:40 AM

-- January 22, 2024 --

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient Globe Newswire 6:40 AM

-- January 16, 2024 --

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data Globe Newswire 6:40 AM

-- January 12, 2024 --

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results Globe Newswire 6:44 AM

-- January 11, 2024 --

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Globe Newswire 6:40 AM

-- January 8, 2024 --

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia Globe Newswire 6:30 AM

-- January 3, 2024 --

Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 Globe Newswire 8:30 AM

-- December 19, 2023 --

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation Globe Newswire 8:30 AM

-- December 12, 2023 --

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform Globe Newswire 8:30 AM

-- December 5, 2023 --

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe Globe Newswire 8:30 AM